Theseus Pharmaceuticals to Present Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting

On March 8, 2022 Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, reported that the Company will present a poster highlighting the characterization of potent and selective next-generation EGFR inhibitors at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 Annual Meeting, being held April 8-13, 2022 in New Orleans, Louisiana (Press release, Theseus Pharmaceuticals, MAR 8, 2022, View Source [SID1234609723]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:
Abstract Title: Discovery of potent and selective next-generation EGFR inhibitors with activity against single, double, and triple mutant EGFR variants including T790M and C797S
Abstract Number: 3342
Presenter: Wei-Sheng Huang, Ph.D., Vice President of Chemistry
Session Date and Time: Tuesday, April 12th, 1:30pm-5pm CT

The presentation will detail the characterization of compounds that potently inhibit the kinase activity, both in vitro and in vivo, of single, double, and triple mutant EGFR variants including T790M and C797S, with selectivity over wild-type EGFR and the ability to penetrate the central nervous system. These variants comprise all major classes of EGFR activating and resistance mutations that contribute to later-line clonal heterogeneity in patients who have been failed by current approved therapies.

EGFR activating mutations are observed in 10-50 percent of non-small cell lung cancer (NSCLC) patients and are initially sensitive to first, second, and third generation EGFR inhibitors. However, on-target resistance is observed in a substantial percentage of patients, with T790M and C797S mutations observed most frequently.